MedTrace Logo

Early Diabetes Intervention Program

NCT01470937 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2011-11-11

No results posted yet for this study

Summary

This is an evaluation of the effect of acarbose to delay worsening of fasting glucose control in early Type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Acarbose

acarbose 100 mg PO once daily

DRUG

Placebo

acarbose placebo

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Indiana University School of Medicine

    lead OTHER

Principal Investigators

  • Kieren J Mather, MD · Indiana University

  • Robert V Considine, PhD · Indiana University

  • Marian S Kirkman, MD · Indiana University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-02-28
Primary Completion
2004-09-30
Completion
2004-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01470937 on ClinicalTrials.gov